240 related articles for article (PubMed ID: 25839337)
21. To what extent do the PANSS and CGI-S overlap?
Rabinowitz J; Mehnert A; Eerdekens M
J Clin Psychopharmacol; 2006 Jun; 26(3):303-7. PubMed ID: 16702895
[TBL] [Abstract][Full Text] [Related]
22. Associations between symptom severity and well-being among Thai patients with schizophrenia: a cross-sectional analytical study.
Teetharatkul T; Vitayanont A; Liabsuetrakul T; Aunjitsakul W
BMC Psychiatry; 2021 Jul; 21(1):348. PubMed ID: 34253169
[TBL] [Abstract][Full Text] [Related]
23. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.
Dunayevich E; Sethuraman G; Enerson M; Taylor CC; Lin D
Schizophr Res; 2006 Sep; 86(1-3):300-8. PubMed ID: 16860974
[TBL] [Abstract][Full Text] [Related]
25. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI.
Levine SZ; Rabinowitz J; Engel R; Etschel E; Leucht S
Schizophr Res; 2008 Jan; 98(1-3):318-22. PubMed ID: 17949948
[TBL] [Abstract][Full Text] [Related]
26. Clinical global impression of cognition in schizophrenia (CGI-CogS): reliability and validity of a co-primary measure of cognition.
Ventura J; Cienfuegos A; Boxer O; Bilder R
Schizophr Res; 2008 Nov; 106(1):59-69. PubMed ID: 17900866
[TBL] [Abstract][Full Text] [Related]
27. The effects of clozapine on symptom clusters in treatment-refractory patients.
Abraham G; Nair C; Tracy JI; Simpson GM; Josiassen RC
J Clin Psychopharmacol; 1997 Feb; 17(1):49-53. PubMed ID: 9004057
[TBL] [Abstract][Full Text] [Related]
28. Clinical implications of Brief Psychiatric Rating Scale scores.
Leucht S; Kane JM; Kissling W; Hamann J; Etschel E; Engel R
Br J Psychiatry; 2005 Oct; 187():366-71. PubMed ID: 16199797
[TBL] [Abstract][Full Text] [Related]
29. The effectiveness of long-acting injectable risperidone in a population of psychiatric out-patients: 1-year naturalistic study.
Di Lorenzo R; Fiorini F; Santachiara S
Psychopharmacol Bull; 2010; 43(1):39-52. PubMed ID: 20581799
[TBL] [Abstract][Full Text] [Related]
30. Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis.
Siafis S; Brandt L; McCutcheon RA; Gutwinski S; Schneider-Thoma J; Bighelli I; Kane JM; Arango C; Kahn RS; Fleischhacker WW; McGorry P; Carpenter WT; Falkai P; Hasan A; Marder SR; Schooler N; Engel RR; Honer WG; Buchanan RW; Davidson M; Weiser M; Priller J; Davis JM; Howes OD; Correll CU; Leucht S
Lancet Psychiatry; 2024 Jan; 11(1):36-46. PubMed ID: 38043562
[TBL] [Abstract][Full Text] [Related]
31. Psychosocial functioning and health-related quality of life in children and adolescents treated with open-label ziprasidone for bipolar mania, schizophrenia, or schizoaffective disorder.
Stewart M; DelBello MP; Versavel M; Keller D
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):635-40. PubMed ID: 20035581
[TBL] [Abstract][Full Text] [Related]
32. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials.
Buckley PF
Curr Med Res Opin; 2004 Sep; 20(9):1357-63. PubMed ID: 15383183
[TBL] [Abstract][Full Text] [Related]
34. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
[TBL] [Abstract][Full Text] [Related]
35. Symptom rating scales and outcome in schizophrenia.
Mortimer AM
Br J Psychiatry Suppl; 2007 Aug; 50():s7-14. PubMed ID: 18019038
[TBL] [Abstract][Full Text] [Related]
36. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
[TBL] [Abstract][Full Text] [Related]
37. Symptom correlates of global measures of severity in schizophrenia.
Goldman M; DeQuardo JR; Tandon R; Taylor SF; Jibson M
Compr Psychiatry; 1999; 40(6):458-61. PubMed ID: 10579378
[TBL] [Abstract][Full Text] [Related]
38. Relationships between global assessment of functioning and other rating scales in clinical trials for schizophrenia.
Suzuki T; Uchida H; Sakurai H; Ishizuki T; Tsunoda K; Takeuchi H; Mimura M
Psychiatry Res; 2015 Jun; 227(2-3):265-9. PubMed ID: 25882098
[TBL] [Abstract][Full Text] [Related]
39. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
[TBL] [Abstract][Full Text] [Related]
40. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
